Lanzhou Foci Pharmaceutical Co Ltd Asset Resilience Ratio
Lanzhou Foci Pharmaceutical Co Ltd asset resilience ratio. Lanzhou Foci Pharmaceutical Co Ltd (002644) has an Asset Resilience Ratio of 0.08% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Lanzhou Foci Pharmaceutical Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lanzhou Foci Pharmaceutical Co Ltd (2015–2022)
Asset resilience ratio of Lanzhou Foci Pharmaceutical Co Ltd from 2015 to 2022. This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read total liabilities of Lanzhou Foci Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Lanzhou Foci Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.00 Million | 0.08% |
| Total Liquid Assets | CN¥2.00 Million | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Lanzhou Foci Pharmaceutical Co Ltd maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lanzhou Foci Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Lanzhou Foci Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
Lanzhou Foci Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2015–2022)
Lanzhou Foci Pharmaceutical Co Ltd asset resilience ratio by year from 2015 to 2022. The table below shows the annual Asset Resilience Ratio data for Lanzhou Foci Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 0.08% | CN¥2.00 Million ≈ $292.89K |
CN¥2.59 Billion ≈ $378.50 Million |
-1.27pp |
| 2020-12-31 | 1.34% | CN¥32.08 Million ≈ $4.69 Million |
CN¥2.39 Billion ≈ $349.32 Million |
+1.23pp |
| 2018-12-31 | 0.11% | CN¥2.90 Million ≈ $424.36K |
CN¥2.52 Billion ≈ $369.34 Million |
-27.87pp |
| 2017-12-31 | 27.98% | CN¥657.50 Million ≈ $96.21 Million |
CN¥2.35 Billion ≈ $343.85 Million |
-6.04pp |
| 2016-12-31 | 34.03% | CN¥693.00 Million ≈ $101.41 Million |
CN¥2.04 Billion ≈ $298.04 Million |
+17.73pp |
| 2015-12-31 | 16.29% | CN¥222.00 Million ≈ $32.49 Million |
CN¥1.36 Billion ≈ $199.36 Million |
-- |
About Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more